Research
Hormonal
GEP44 promotes insulin-independent glucose uptake in muscle tissue via Y1 receptor agonism, distinct from the insulin-dependent pathway.
This mechanism suggests that future obesity drugs might improve blood sugar control in muscles even without triggering insulin release, potentially offering benefits for insulin resistance.
ModerateSupportsMEDIUM confidence
GEP44 activates insulin-independent glucose uptake in muscle tissue via its interactions with Y1-R... wortmannin had no impact on glucose uptake stimulated by the Y-1R agonist, PYY1-36.
Why this rating
Ex vivo rat muscle tissue study.
Source
A Peptide Triple Agonist of GLP-1, Neuropeptide Y1, and Neuropeptide Y2 Receptors Promotes Glycemic Control and Weight Loss
Kylie S. Chichura et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2022
DOI 10.1101/2022.11.07.515458
preprintCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →